Literature DB >> 9272737

Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance.

J R Lo Ten Foe1, M L Kwee, M A Rooimans, A B Oostra, A J Veerman, M van Weel, R M Pauli, N T Shahidi, I Dokal, I Roberts, C Altay, E Gluckman, R A Gibson, C G Mathew, F Arwert, H Joenje.   

Abstract

Approximately 25% of patients with Fanconi anemia (FA) have evidence of spontaneously occurring mosaicism as manifest by the presence of two subpopulations of lymphocytes, one of which is hypersensitive to cross-linking agents (e.g. mitomycin C) while the other behaves normally in response to these agents. The molecular basis of this phenotypic reversion has not yet been determined. We have investigated 8 FA patients with evidence of mosaicism. Epstein-Barr virus-immortalized lymphoblastoid cell lines established from these patients exhibited an IC50 for mitomycin C of 25 to > 100 nM compared to a mean of 2 +/- 2 nM for 20 nonmosaic FA patients and 49 +/- 11 nM for 8 healthy controls. In 3 patients who were compound heterozygotes for pathogenic FAC gene mutations the molecular mechanism of the mosaicism was investigated by haplotype analysis. The results indicated that an intragenic mitotic recombination must have occurred leading to a segregation of a wild-type allele in the reverted cells and suggested two patterns of recombination. In 1 patient a single intragenic crossover between the maternally and paternally inherited mutations occurred associated with markers located distally to the FAC gene; in the other 2 patients (sibs) the mechanism appears to have been gene conversion resulting in segregants which have lost one pathogenic mutation. In 6 of the 8 patients the hematological symptoms were relatively mild despite an age range of 9-30 years.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9272737

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  65 in total

1.  Complementation analysis in Fanconi anemia: assignment of the reference FA-H patient to group A.

Authors:  H Joenje; M Levitus; Q Waisfisz; A D'Andrea; I Garcia-Higuera; T Pearson; C G van Berkel; M A Rooimans; N Morgan; C G Mathew; F Arwert
Journal:  Am J Hum Genet       Date:  2000-08-08       Impact factor: 11.025

Review 2.  Fanconi anaemia.

Authors:  M D Tischkowitz; S V Hodgson
Journal:  J Med Genet       Date:  2003-01       Impact factor: 6.318

3.  Gene therapy for Fanconi anemia: one step closer to the clinic.

Authors:  Jakub Tolar; Pamela S Becker; D Wade Clapp; Helmut Hanenberg; Cristina Díaz de Heredia; Hans-Peter Kiem; Susana Navarro; Pankaj Qasba; Paula Rio; Manfred Schmidt; Julián Sevilla; Els Verhoeyen; Adrian J Thrasher; Juan Bueren
Journal:  Hum Gene Ther       Date:  2012-02       Impact factor: 5.695

4.  Somatic mosaicism in Wiskott--Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism.

Authors:  T Wada; S H Schurman; M Otsu; E K Garabedian; H D Ochs; D L Nelson; F Candotti
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

Review 5.  Somatic mosaicism: on the road to cancer.

Authors:  Luis C Fernández; Miguel Torres; Francisco X Real
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

Review 6.  Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.

Authors:  Mary Ellen Moynahan; Maria Jasin
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03       Impact factor: 94.444

7.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Authors:  Raphael Ceccaldi; Delphine Briot; Jérôme Larghero; Nadia Vasquez; Catherine Dubois d'Enghien; Delphine Chamousset; Maria-Elena Noguera; Quinten Waisfisz; Olivier Hermine; Corinne Pondarre; Thierry Leblanc; Eliane Gluckman; Hans Joenje; Dominique Stoppa-Lyonnet; Gérard Socié; Jean Soulier
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

8.  Cytokinesis failure and attenuation: new findings in Fanconi anemia.

Authors:  Philip J Mason; Monica Bessler
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

9.  Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4.

Authors:  Yonghwan Kim; Gabriella S Spitz; Uma Veturi; Francis P Lach; Arleen D Auerbach; Agata Smogorzewska
Journal:  Blood       Date:  2012-10-23       Impact factor: 22.113

10.  Anti-Müllerian hormone deficiency in females with Fanconi anemia.

Authors:  Martha M Sklavos; Neelam Giri; Pamela Stratton; Blanche P Alter; Ligia A Pinto
Journal:  J Clin Endocrinol Metab       Date:  2014-01-17       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.